Tomoyuki Ohe

2.4k total citations
61 papers, 1.3k citations indexed

About

Tomoyuki Ohe is a scholar working on Molecular Biology, Organic Chemistry and Pharmacology. According to data from OpenAlex, Tomoyuki Ohe has authored 61 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 17 papers in Organic Chemistry and 16 papers in Pharmacology. Recurrent topics in Tomoyuki Ohe's work include Pharmacogenetics and Drug Metabolism (15 papers), Neuropeptides and Animal Physiology (9 papers) and Receptor Mechanisms and Signaling (9 papers). Tomoyuki Ohe is often cited by papers focused on Pharmacogenetics and Drug Metabolism (15 papers), Neuropeptides and Animal Physiology (9 papers) and Receptor Mechanisms and Signaling (9 papers). Tomoyuki Ohe collaborates with scholars based in Japan, United States and China. Tomoyuki Ohe's co-authors include Tadahiko Mashino, Masaaki Hirobe, Masato Chiba, Masayo Yamazaki, Jiunn H. Lin, Jerome Hochman, Kyôko Takahashi, Shigeo Nakamura, I‐Wu Chen and William Neway and has published in prestigious journals such as PLoS ONE, Biochemical and Biophysical Research Communications and International Journal of Molecular Sciences.

In The Last Decade

Tomoyuki Ohe

58 papers receiving 1.3k citations

Peers

Countries citing papers authored by Tomoyuki Ohe

Since Specialization

Citations

This map shows the geographic impact of Tomoyuki Ohe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomoyuki Ohe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomoyuki Ohe more than expected).

Fields of papers citing papers by Tomoyuki Ohe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomoyuki Ohe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomoyuki Ohe. The network helps show where Tomoyuki Ohe may publish in the future.

Co-authorship network of co-authors of Tomoyuki Ohe

This figure shows the co-authorship network connecting the top 25 collaborators of Tomoyuki Ohe. A scholar is included among the top collaborators of Tomoyuki Ohe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomoyuki Ohe. Tomoyuki Ohe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease 2022 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Daisuke Yasuda, Kyôko Takahashi, Shigeo Nakamura, Tadahiko Mashino, Tomoyuki Ohe	8
2	Synthesis and evaluation of tofacitinib analogs designed to mitigate metabolic activation 2021 ·Drug Metabolism and Pharmacokinetics ·(unknown), (unknown), Kyôko Takahashi, Shigeo Nakamura, Yasuhiro Kazuki, Tadahiko Mashino, Tomoyuki Ohe	4
3	Inhibitors of the protein–protein interaction between phosphorylated p62 and Keap1 attenuate chemoresistance in a human hepatocellular carcinoma cell line 2020 ·Free Radical Research ·Daisuke Yasuda, Tomoyuki Ohe, Kyôko Takahashi, Riyo Imamura, Hirotatsu Kojima, Takayoshi Okabe, Yoshinobu Ichimura, Masaaki Komatsu, Masayuki Yamamoto, Tetsuo Nagano, Tadahiko Mashino	28
4	Synthesis and evaluation of nevirapine analogs to study the metabolic activation of nevirapine 2020 ·Drug Metabolism and Pharmacokinetics ·(unknown), Tomoyuki Ohe, Daisuke Yasuda, Kyôko Takahashi, Shigeo Nakamura, Yasuhiro Kazuki, Tadahiko Mashino	5
5	Fullerene derivatives as dual inhibitors of HIV-1 reverse transcriptase and protease 2020 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Tomoyuki Ohe, Hiroki Kataoka, (unknown), Yumiko Ishikawa, (unknown), (unknown), (unknown), Kyôko Takahashi, Shigeo Nakamura, Tadahiko Mashino	22
6	N-Acetyl cysteine prevents activities of STAT3 inhibitors, Stattic and BP-1-102 independently of its antioxidant properties 2019 ·Pharmacological Reports ·(unknown), Tomoyuki Ohe, Tadahiko Mashino, (unknown), Kenji Tago, Hiroomi Tamura, Megumi Funakoshi‐Tago	9
7	<p>Synthesis and antitumor activity of novel pyridinium fullerene derivatives</p> 2019 ·International Journal of Nanomedicine ·(unknown), Tomoyuki Ohe, H. Ikeda, Kyôko Takahashi, Shigeo Nakamura, Tadahiko Mashino	17
8	Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK 2017 ·PLoS ONE ·(unknown), (unknown), Kenji Tago, Yosuke Nakazawa, Tomoyuki Ohe, Tadahiko Mashino, (unknown), Tadashi Kasahara, Hiroomi Tamura, Megumi Funakoshi‐Tago	12
9	Synthesis of Keap1-phosphorylated p62 and Keap1-Nrf2 protein-protein interaction inhibitors and their inhibitory activity 2016 ·Bioorganic & Medicinal Chemistry Letters ·Daisuke Yasuda, (unknown), Akihiro Yuasa, Rika Obata, Kyôko Takahashi, Tomoyuki Ohe, Yoshinobu Ichimura, Masaaki Komatsu, Masayuki Yamamoto, Riyo Imamura, Hirotatsu Kojima, Takayoshi Okabe, Tetsuo Nagano, Tadahiko Mashino	38
10	A proline-type fullerene derivative inhibits adipogenesis by preventing PPARγ activation 2016 ·Biochemistry and Biophysics Reports ·Megumi Funakoshi‐Tago, Takahiro Hattori, (unknown), Kenji Tago, Tomoyuki Ohe, Tadahiko Mashino, Hiroomi Tamura	1
11	Novel fullerene derivatives as dual inhibitors of Hepatitis C virus NS5B polymerase and NS3/4A protease 2016 ·Bioorganic & Medicinal Chemistry Letters ·Hiroki Kataoka, Tomoyuki Ohe, Kyôko Takahashi, Shigeo Nakamura, Tadahiko Mashino	30
12	Novel Bioactivation Pathway of Benzbromarone Mediated by Cytochrome P450 2015 ·Drug Metabolism and Disposition ·(unknown), Tomoyuki Ohe, (unknown), Kyôko Takahashi, Shigeo Nakamura, Tadahiko Mashino	16
13	Effect of chemical modification on the ability of pyrrolidinium fullerene to induce apoptosis of cells transformed by JAK2 V617F mutant 2014 ·International Immunopharmacology ·Megumi Funakoshi‐Tago, (unknown), Toshiro Watanabe, (unknown), Kenji Tago, Tomoyuki Ohe, Shigeo Nakamura, Tadahiko Mashino, Tadashi Kasahara	10
14	Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs 2011 ·Molecular Pharmacology ·Jun‐ichi Eiki, Yasufumi Nagata, Mayumi Futamura, (unknown), Tomoharu Iino, T. Nishimura, Masato Chiba, Sumika Ohyama, (unknown), Kenji Fujii, Hideka Hosaka, (unknown), (unknown), Tomoyuki Ohe, Songnian Lin, Ronald B. Langdon, Joel P. Berger	25
15	Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists 2009 ·Bioorganic & Medicinal Chemistry Letters ·Toshiyuki Takahashi, Yuji Haga, Toshihiro Sakamoto, Minoru Moriya, Osamu Okamoto, Katsumasa Nonoshita, Takunobu Shibata, Takuya Suga, (unknown), Tomoko Hirohashi, (unknown), Akira Gomori, Hisashi Iwaasa, Tomoyuki Ohe, Akane Ishihara, Yasuyuki Ishii, Akio Kanatani, Takehiro Fukami	13
16	5,5-Dimethyl-3-(5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1-phenyl-3-(trifluoromethyl)-3,5,6,7-tetrahydro-1H-indole-2,4-dione, a Potent Inhibitor for Mammalian Elongase of Long-Chain Fatty Acids Family 6: Examination of Its Potential Utility as a Pharmacological Tool 2009 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown), Hidefumi Kitazawa, Yasuhisa Miyamoto, (unknown), Akira Nagumo, Ryo Yoshimoto, Katsumi Aragane, (unknown), Tomoyuki Ohe, Toshiyuki Takahashi, Tsuyoshi Nagase, Nagaaki Sato, Shigeru Tokita	13
17	A Trapping Method for Semi-quantitative Assessment of Reactive Metabolite Formation Using [35S]Cysteine and [14C]Cyanide 2009 ·Drug Metabolism and Pharmacokinetics ·Kazuko Inoue, Yoshihiro Shibata, Hiroyuki Takahashi, Tomoyuki Ohe, Masato Chiba, Yasuyuki Ishii	23
18	Evaluation methods for reactive metabolites 2009 ·Folia Pharmacologica Japonica ·Tomoyuki Ohe	2
19	Syntheses and structure–activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists 2008 ·Bioorganic & Medicinal Chemistry Letters ·Yoshio Ogino, Norikazu Ohtake, (unknown), Kenji Matsuda, Makoto Ishikawa, Minoru Moriya, (unknown), Yuko Mitobe, Junko Itô, Tetsuya Kanno, Akane Ishihara, Hisashi Iwaasa, Tomoyuki Ohe, Akio Kanatani, Takehiro Fukami	19
20	Novel Metabolic Pathway of Arylethers by Cytochrome P450: Cleavage of the Oxygen-Aromatic Ring Bond Accompanying ipso-Substitution by the Oxygen-Atom of the Active Species in Cytochrome P450 Models and Cytochrome P450 1994 ·Archives of Biochemistry and Biophysics ·Tomoyuki Ohe, (unknown), Masaaki Hirobe	52

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact